Diffusion imaging for evaluation of tumor therapies in preclinical animal models

被引:91
作者
Moffat, BA
Hall, DE
Stojanovska, J
McConville, PJ
Moody, JB
Chenevert, TL
Rehemtulla, A
Ross, BD
机构
[1] Univ Michigan, Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[3] Mol Imaging Res, Ann Arbor, MI 48104 USA
关键词
apparent diffusion coefficient; ADC; diffusion; tumor; therapeutic efficacy; MRI; NMR;
D O I
10.1007/s10334-004-0079-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The increasing development of novel targeted therapies for treating solid tumors has necessitated the development of technology to determine their efficacy in preclinical animal models. One such technology that can non-invasively quantify early changes in tumor cellularity as a result of an efficacious therapy is diffusion MRI. In this overview we present some theories as to the origin of diffusion changes as a result of tumor therapy, a robust methodology for acquisition of apparent diffusion coefficient maps and some applications of determining therapeutic efficacy in a variety therapeutic regimens and animal models.
引用
收藏
页码:249 / 259
页数:11
相关论文
共 33 条
[1]   ANALYSIS AND CORRECTION OF MOTION ARTIFACTS IN-DIFFUSION WEIGHTED IMAGING [J].
ANDERSON, AW ;
GORE, JC .
MAGNETIC RESONANCE IN MEDICINE, 1994, 32 (03) :379-387
[2]  
BARKER M, 1973, CANCER RES, V33, P976
[3]  
BRUNBERG JA, 1995, AM J NEURORADIOL, V16, P361
[4]   Diffusion MRI: A new strategy for assessment of cancer therapeutic efficacy [J].
Chenevert, Thomas L. ;
Meyer, Charles R. ;
Moffat, Bradford A. ;
Rehemtulla, Alnawaz ;
Mukherji, Suresh K. ;
Gebarski, Stephen S. ;
Quint, Douglas J. ;
Robertson, Patricia L. ;
Lawrence, Theodore S. ;
Junck, Larry ;
Taylor, Jeremy M.G. ;
Johnson, Timothy D. ;
Dong, Qian ;
Muraszko, Karin M. ;
Brunberg, James A. ;
Ross, Brian D. .
Molecular Imaging, 2002, 1 (04) :336-343
[5]  
Chenevert TL, 1997, CLIN CANCER RES, V3, P1457
[6]   Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors [J].
Chenevert, TL ;
Stegman, LD ;
Taylor, JMG ;
Robertson, PL ;
Greenberg, HS ;
Rehemtulla, A ;
Ross, BD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (24) :2029-2036
[7]  
Crafts D, 1977, Natl Cancer Inst Monogr, V46, P11
[8]   THE USE OF ANIMAL-MODELS IN CANCER DRUG DISCOVERY AND DEVELOPMENT [J].
CURT, GA .
STEM CELLS, 1994, 12 (01) :23-29
[9]  
Galons Jean-Philippe, 1999, Neoplasia (New York), V1, P113, DOI 10.1038/sj.neo.7900009
[10]  
Hakumäki JM, 1998, CANCER RES, V58, P3791